← FDA DRUG APPROVALS

FDA ANDA · ANDA202063

GEMCITABINE HYDROCHLORIDE

Sponsor: EMCURE PHARMS LTD

APPLICATION
ANDA202063
TYPE
ANDA
ORIGINAL APPROVAL
2012-09-11
LATEST ACTION
2019-11-14
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE EQ 200MG BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2019-11-14Labeling · Supplement 9 · standardAP
2019-11-14Labeling · Supplement 7 · standardAP
2019-11-14Labeling · Supplement 8 · standardAP
2015-11-27Labeling · Supplement 3 · standardAP
2015-11-27Labeling · Supplement 1 · standardAP
2015-11-27Labeling · Supplement 4 · standardAP
2012-09-11Not Applicable · OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →